NO donor hybrid compounds as multifunctional therapeutic agents

Bibliography

• Miller MR, Megson IL. Recent developments in nitric oxide donor drugs. Brit J Pharmacol 2007;151:305-21
   PubMed Web of Science ®Google Scholar
• Brunner H, Cockcroft JR, Deanfield J. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the working group on endothelins and endothelial factors of the european society of hypertension. J Hypertens 2005;23:233-46
   PubMed Web of Science ®Google Scholar
• Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-4
   PubMed Web of Science ®Google Scholar
• Keeble JE, Moore PK. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal antiinflammatory and related nitric oxide-donating drugs. Br J Pharmacol 2002;137:295-310
   PubMed Web of Science ®Google Scholar
• Wang PG, Xian M, Tang X, et al. Nitric oxide donors: chemical activities and biological applications. Chem Rev 2002;102:1091-134
   PubMed Web of Science ®Google Scholar
• Burgaud JL, Ongini E, Del Soldato P. Nitric oxide-releasing drugs: a novel class of effective and safe therapeutic agents. Ann N Y Acad Sci 2002;962:360-71
   PubMed Web of Science ®Google Scholar
• Burgaud JL, Riffaud JP, Del Soldato P. Nitric-oxide releasing molecules: a new class of drugs with several major indications. Curr Pharm Des 2002;8:201-13
   PubMedGoogle Scholar
• CAL Int. Ltd. WO9403421; 1994
   Google Scholar
• Al-Sa'doni HH, Ferro A. S-Nitrosothiols as nitric oxide-donors: chemistry, biology and possible future therapeutic applications. Curr Med Chem 2004;11:2679-90
   PubMed Web of Science ®Google Scholar
• Wang K, Zhang W, Xian M, et al. New chemical and biological aspects of S-nitrosothiols. Curr Med Chem 2000;7:821-34
   PubMed Web of Science ®Google Scholar
• Lehmann J. Nitric oxide donors – current trends in therapeutic applications. Exp Opin Ther Patents 2000;10:559-74
   Web of Science ®Google Scholar
• Gibbons GH. Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am J Cardiol 1997;79:3-8
   PubMedGoogle Scholar
• Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004;109:27-32
   Web of Science ®Google Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115-26
   PubMed Web of Science ®Google Scholar
• Behrendt D, Ganz P. Endothelial function: from vascular biology to clinical applications. Am J Cardiol 2002;90:40-8
   PubMed Web of Science ®Google Scholar
• Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12
   PubMed Web of Science ®Google Scholar
• Perticone F, Ceravolo R, Pujia A. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001;104:191-6
   PubMed Web of Science ®Google Scholar
• Nicox S.A. WO9821193; 1998
   Google Scholar
• Nitromed, Inc. WO2002087508; 2002
   Google Scholar
• Yissum research development company of the hebrew university of jerusalem. WO2004047837; 2004
   Google Scholar
• Nicox S.A. WO2005053685; 2005
   Google Scholar
• Nitromed, Inc. WO2006078995; 2006
   Google Scholar
• Nicox S.A. WO2005054218; 2005
   Google Scholar
• Nicox S.A. WO2006079610; 2006
   Google Scholar
• Nicox S.A. WO2007137980; 2007
   Google Scholar
• Nicox S.A. WO2005011646; 2005
   Google Scholar
• Li YQ, Ji H, Zhang Y-H, et al. WB1106, a novel nitric oxide-releasing derivative of telmisartan, inhibits hypertension and improves glucose metabolism in rats. Eur J Pharmacol 2007;577:100-8
   PubMed Web of Science ®Google Scholar
• Ichiki T, Usui M, Kato M. Downregulation of angiotensin II type 1 receptor gene transcription by nitric oxide. Hypertension 1998;31:342-8
   PubMed Web of Science ®Google Scholar
• Nicox S.A. WO2004106300; 2004
   Google Scholar
• Nicox S.A. WO2004110432; 2004
   Google Scholar
• Nicox S.A. WO2007104652; 2007
   Google Scholar
• Nicox S.A. WO2007090733; 2007
   Google Scholar
• Lehmann J, Kahlich R, Meyer zum Gottesberge C, et al. Organic nitrates. II. Synthesis and biological activities of 4-nitrooxymethylphenyl-1,4-dihydropyridines. Arch Pharm (Weinheim) 1997;330:247-52
   PubMedGoogle Scholar
• Nitromed, Inc. WO2006055542; 2006
   Google Scholar
• Nicox S.A. WO9716405; 1997
   Google Scholar
• Rainsford KD, Whitehouse MW. Gastric irritancy of aspirin and its congeners: anti-inflammatory activity without this side-effect. J Pharm Pharmacol 1976;28:599-601
   PubMedGoogle Scholar
• Wallace JL, Mcknight W, Del Soldato P, et al. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest 1995;96:2711-8
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Del Soldato P. NO-aspirin: mechanism of action and gastrointestinal safety. Dig Liver Dis 2003;35(Suppl 2):9-19
   PubMedGoogle Scholar
• Cena C, Lolli ML, Lazzarato L, et al. Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin. J Med Chem 2003;46:747-54
   PubMed Web of Science ®Google Scholar
• Turnbull CM, Rossi AG, Megson IL. Therapeutic effects of nitric oxide-aspirin hybrid drugs. Expert Opin Ther Targets 2006;10:911-22
   PubMed Web of Science ®Google Scholar
• Nicox S.A. WO2002100400; 2002
   Google Scholar
• Nicox S.A. WO2007060112; 2007
   Google Scholar
• Lacer S.A. WO0044714; 2000
   Google Scholar
• Nicox S.A. WO2003013499; 2003
   Google Scholar
• Stuart-Smith K. Demystified nitric oxide. Mol Pathol 2002;55:360-6
   PubMedGoogle Scholar
• Nicox S.A. WO2004105754; 2004
   Google Scholar
• Nicox S.A. WO2007045551; 2007
   Google Scholar
• Nicox S.A. WO2003080568; 2003
   Google Scholar
• Brunelli S, Rovere-Querini P, Sciorati C, et al. Nitric oxide: emerging concepts about its use in cell-based therapies. Expert Opin Investig Drugs 2007;16:33-43
   PubMed Web of Science ®Google Scholar
• Tripathi P, Tripathi P, Kashyap L, et al. The role of nitric oxide in inflammatory reactions. FEMS Immunol Med Microbiol 2007;51:443-52
   PubMed Web of Science ®Google Scholar
• Cathella-Lawson F, Reilly MP, Kapoor SC. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17
   PubMedGoogle Scholar
• Vane J, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:2-8
   PubMed Web of Science ®Google Scholar
• Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drugs gastric damage. Am J Med 1989;86:449-57
   PubMed Web of Science ®Google Scholar
• Hollander D. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: prophylactic and therapeutic strategies. Am J Med 1994;96:274-81
   PubMed Web of Science ®Google Scholar
• Soll AH, Weinstein WM, Kurata J, et al. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991;114:307-19
   PubMed Web of Science ®Google Scholar
• Wallace JL, Miller MJ. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology 2000;119:512-20
   PubMed Web of Science ®Google Scholar
• Brown JF, Keates AC, Hanson PJ, et al. Nitric oxide generators and cGMP stimulate mucus secretion by rat gastric mucosal cells. Am J Physiol 1993;265(3 Pt 1):418-22
   PubMed Web of Science ®Google Scholar
• Ma L, Wallace JL. Endothelial nitric oxide synthase modulates gastric ulcer healing in rats. Am J Physiol Gastrointest Liver Physiol 2000;279:341-6
   PubMed Web of Science ®Google Scholar
• Nicox S.A. WO9530641; 1995
   Google Scholar
• Nicox S.A. WO9731654; 1997
   Google Scholar
• Nicox S.A. WO0051988; 2000
   Google Scholar
• Nicox S.A. WO0230866; 2002
   Google Scholar
• Nitromed, Inc. WO02060378; 2002
   Google Scholar
• Nitromed, Inc. WO03103602; 2003
   Google Scholar
• Pharmacia corporation. WO20050233189; 2005
   Google Scholar
• Hoogstraate J, Andersson LI, Berge OG, et al. COX-inhibiting nitric oxide donators (CINODs)-a new paradigm in the treatment of pain and inflammation. Inflammopharmacology 2003;11:423-8
   PubMedGoogle Scholar
• Moore PK, Marshall M. Nitric oxide releasing acetaminophen (nitroacetaminophen). Dig Liver Dis 2003;35(S2):49-60
   PubMedGoogle Scholar
• FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2:879-90
   PubMed Web of Science ®Google Scholar
• Dogne JM, Supuran CT, Pratico D. Adverse cardiovascular effects of the coxibs. J Med Chem 2005;48:2251-7
   PubMed Web of Science ®Google Scholar
• Merck Frosst Canada & Co. WO2004037798; 2004
   Google Scholar
• Lundy KM, Clark MT. US20010012851; 2001
   Google Scholar
• Merck Frosst Canada & Co. WO2004011421; 2004
   Google Scholar
• Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43
   PubMed Web of Science ®Google Scholar
• Nicox S.A. WO9815568; 1998
   Google Scholar
• Nicox S.A. WO0061604; 2000
   Google Scholar
• Nicox S.A. WO03064443; 2003
   Google Scholar
• Keeble J, al-Swayeh OA, Moore PK. Vasorelaxant effect of nitric oxide releasing steroidal and non steroidal anti-inflammatory drugs. Br J Pharmacol 2001;133:1023-8
   PubMedGoogle Scholar
• Di Filippo C, Rossi F, Ongini E, et al. The distinct alterations produced in cardiovascular functions by prednisolone and nitro-prednisolone (NCX-1015) in the rat highlight a causal role for endothelin-1. J Pharmacol Exp Ther 2004;310:1133-41
   PubMedGoogle Scholar
• Bolla1 M, Almirante N, Benedini F. Therapeutic potential of nitrate esters of commonly used drugs. Curr Top Med Chem 2005;5:707-20
   PubMedGoogle Scholar
• Fang L, Zhang Y, Lehmann J, et al. Design and synthesis of furoxan-based nitric oxide-releasing glucocorticoid derivatives with potent anti-inflammatory activity and improved safety. Bioorg Med Chem Lett 2007;17:1062-6
   PubMed Web of Science ®Google Scholar
• Nitromed, Inc. WO20040024014; 2004
   Google Scholar
• Sorba G, Galli U, Cena C, et al. A new furoxan NO-donor rabeprazole derivative and related compounds. ChemBioChem 2003;4:899-903
   PubMed Web of Science ®Google Scholar
• Astrazeneca AB. WO0200166; 2002
   Google Scholar
• Nicox S.A. WO9945004; 1999
   Google Scholar
• Mégraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998;115:1278-82
   PubMed Web of Science ®Google Scholar
• Colasanti M, Persichini T. Nitric oxide: an inhibitor of NFkB/Rel system in glyal cells. Brain Res Bull 2000;52:155-61
   PubMed Web of Science ®Google Scholar
• Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12
   PubMed Web of Science ®Google Scholar
• Tang X, Cai T, Wang PG. Synthesis of beta-lactamase activated nitric oxide donors. Bioorg Med Chem Lett 2003;13:1687-90
   PubMedGoogle Scholar
• Nitromed, Inc. WO2007016677; 2007
   Google Scholar
• Nitromed, Inc. WO2005070006; 2005
   Google Scholar
• Khalili P, Naimi E, Sun WY, et al. Biochemical and pharmacokinetic evaluation of a novel pyrimidine nucleoside nitric oxide donor as a potential anticancer/antiviral agent. Eur J Pharm Sci 2003;19:305-13
   PubMed Web of Science ®Google Scholar
• Nicox S.A. WO2004043443; 2004
   Google Scholar
• Garvey DS, de Tejada IS. US20030158184; 2003
   Google Scholar
• Burnett AL. Role of nitric oxide in the physiology of erection. Biol Reprod 1995;52:485-89
   PubMed Web of Science ®Google Scholar
• Extarma AG. WO2007017191; 2007
   Google Scholar
• Nitromed, Inc. US6331543; 2001
   Google Scholar
• Chien W-L, Liang K-C, Teng C-M. Enhancement of learning behaviour by a potent nitric oxide-guanylate cyclase activator YC-1. Eur J Neurosci 2005;21:1679-88
   PubMed Web of Science ®Google Scholar
• Thatcher GR, Bennett BM, Dringenberg HC. Novel nitrates as NO mimetics directed at Alzheimer's disease. J Alzheimers Dis 2004;6:S75-84
   Google Scholar
• Rauhala P, Andoh T, Chiueh CC. Neuroprotective properties of nitric oxide and S-nitrosoglutathione. Toxicol Appl Pharmacol 2005;207:91-5
   PubMedGoogle Scholar
• Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421
   PubMed Web of Science ®Google Scholar
• Togo T, Katsuse O, Iseki E. Nitric oxide pathways in Alzheimer's disease and other neurodegenerative dementias. Neurol Res 2004;26:563-6
   PubMed Web of Science ®Google Scholar
• Nicox S.A. WO00051988; 2000
   Google Scholar
• Laura G, Ennio O, Gary W. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J Neurochem 2004;91:521-36
   PubMedGoogle Scholar
• Rosi S, McGann K, Hauss-Wegrzyniak B, et al. The influence of brain inflammation upon neuronal adenosine A2B receptors. J Neurochem 2003;86:220-7
   PubMed Web of Science ®Google Scholar
• Fang L, Appenroth D, Decker M, et al. Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates. J Med Chem 2008;51:713-6
   PubMed Web of Science ®Google Scholar
• Mocellin S, Bronte V, Nitti D. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev 2007;27:317-52
   PubMed Web of Science ®Google Scholar
• Moharram S, Zhou A, Wiebe LI, et al. Design and synthesis of 3′- and 5′-O-(3-benzenesulfonylfuroxan-4-yl)-2′-deoxyuridines: biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents. J Med Chem 2004;47:1840-6
   PubMed Web of Science ®Google Scholar
• Wong N, Tucker J, McCaffrey DR. US20070099826; 2007
   Google Scholar
• Shami PJ, Parker CJ. US20010029033; 2001
   Google Scholar
• Kashfi K, Rigas B. Molecular targets of nitric-oxide-donating aspirin in cancer. Biochem Soc Trans 2005;33:701-4
   PubMedGoogle Scholar
• Kashfi K, Borgo S, Williams JL, et al. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J Pharmacol Exp Ther 2005;312:978-88
   PubMed Web of Science ®Google Scholar
• Van't Hof RJ, Ralston SH. Nitric oxide and bone. Immunology 2001;103:255
   PubMed Web of Science ®Google Scholar
• Das UN. Nitric oxide as the mediator of the antiosteoporotic actions of estrogen, statins, and essential fatty acids. Exp Biol Med (Maywood) 2002;227:88-93
   PubMedGoogle Scholar
• Lazzarato L, Rolando B, Lolli ML, et al. Synthesis of NO-donor bisphosphonates and their in vitro action on bone resorption. J Med Chem 2005;48:1322-9
   PubMed Web of Science ®Google Scholar
• Osteosreen, Inc. WO03105752; 2003
   Google Scholar
• Ricciardolo FL. Multiple roles of nitric oxide in the air ways. Thorax 2003;58:175-82
   PubMed Web of Science ®Google Scholar
• Nicox S.A. WO0112584; 2001
   Google Scholar
• The Hebrew University of Jerusalem. WO03088961; 2003
   Google Scholar
• China Pharmaceutica University. CN1480455; 2004
   Google Scholar
• Konter J, Abou-Rahma G, El-Emam A, Lehmann J. Synthesis of diazen-1-ium-1,2-diolates monitored by the “NOtizer” apparatus: relationship between formation rates, molekular structure and the release of nitric oxide. Eur J Org Chem 2007;616-24
   Google Scholar
• Gasco A, Fruttero R, Rolando B. Focus on recent approaches for the development of new NO-donors. Mini Rev Med Chem 2005;5:217-29
   PubMed Web of Science ®Google Scholar
• Keefer LK. Nitric oxide (NO)- and nitroxyl (HNO)-generating diazeniumdiolates (NONOates): emerging commercial opportunities. Curr Top Med Chem 2005;5:625-36
   PubMed Web of Science ®Google Scholar
• Wu XJ, Tang XP, Xian M, et al. Glycosylated diazeniumdiolates: a novel class of enzyme- activated nitric oxide donors. Tetrahedron Lett 2001;42:3779-821
   Web of Science ®Google Scholar
• Loureiro-Silva MR, Cadelina GW, Iwakiri Y, et al. A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. J Hepatol 2003;39:940-6
   PubMed Web of Science ®Google Scholar